Joinn Laboratories (China) Co (HKSE:06127) Gross Margin % : 30.28% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Joinn Laboratories (China) Co's Gross Profit for the three months ended in Dec. 2024 was HK$221 Mil. Joinn Laboratories (China) Co's Revenue for the three months ended in Dec. 2024 was HK$729 Mil. Therefore, Joinn Laboratories (China) Co's Gross Margin % for the quarter that ended in Dec. 2024 was 30.28%.

Warning Sign:

Joinn Laboratories (China) Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -9.8%.

The historical rank and industry rank for Joinn Laboratories (China) Co's Gross Margin % or its related term are showing as below:

HKSE:06127' s Gross Margin % Range Over the Past 10 Years
Min: 28.43 Med: 50.92 Max: 56.27
Current: 28.43

During the past 13 years, the highest Gross Margin % of Joinn Laboratories (China) Co was 56.27%. The lowest was 28.43%. And the median was 50.92%.

HKSE:06127's Gross Margin % is ranked worse than
78.43% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: 47.58 vs HKSE:06127: 28.43

Joinn Laboratories (China) Co had a gross margin of 30.28% for the quarter that ended in Dec. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Joinn Laboratories (China) Co was -9.80% per year.

Joinn Laboratories (China) Co Gross Margin % Historical Data

The historical data trend for Joinn Laboratories (China) Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Gross Margin % Chart

Joinn Laboratories (China) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross Margin %

Get a 7-Day Free Trial

51.38

48.73

47.90

42.62

28.43

Joinn Laboratories (China) Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross Margin %	Get a 7-Day Free Trial															40.30	32.84	28.84	22.43	30.28

Competitive Comparison of Joinn Laboratories (China) Co's Gross Margin %

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Joinn Laboratories (China) Co's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Gross Margin % falls into.

Save Embed

;

Save Embed

;

Joinn Laboratories (China) Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Joinn Laboratories (China) Co's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )	=	Gross Profit (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	612.6	/	2154.919
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(2154.919 - 1542.317)	/	2154.919
	=	28.43 %

Joinn Laboratories (China) Co's Gross Margin for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )	=	Gross Profit (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	220.9	/	729.41
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(729.41 - 508.542)	/	729.41
	=	30.28 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Joinn Laboratories (China) Co (HKSE:06127) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Joinn Laboratories (China) Co had a gross margin of 30.28% for the quarter that ended in Dec. 2024 => Competition eroding margins

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Joinn Laboratories (China) Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

603127:China

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Futu Trustee Limited	2301 Trustee
Ubs Group Ag	2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities	2102 Investment manager
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Fidelity Funds	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc	2101 Beneficial owner
Morgan Stanley	2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Apg Asset Management N.v.	2101 Beneficial owner
Apg Groep N.v.	2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines